Abstract 21P
Background
The mutation rate of TP53 in non-small cell lung cancer (NSCLC) ranges from 50% to 60%, but the impact of specific TP53 mutation types on anti-PD-(L)1 therapy efficacy remains unknown.
Methods
A cohort of NSCLC patients without EGFR/ALK/ROS1 mutations was retrospectively assembled and categorized. Enrolled patients received anti-PD-(L)1 immunotherapy, with periodic radiographic evaluation of efficacy, and all participants underwent NGS large panel testing before starting therapy. Chi-square test and survival curve evaluation were subsequently conducted.
Results
From Nov 2021 to Nov 2023, a total of 51 patients were included in TP53-mutant group and 34 in TP53-wild group. There were no significant differences between the two groups regarding gender, age, pathological subtype, driver gene mutation profile (except TP53), TNM staging, PD-L1 TPS, timing of immunotherapy and immunotherapy regimens. As of Sep 25, 2024, the median progression-free survival (mPFS) was 11.43 months (95% CI 7.93-14.93m) in TP53-mutant group and 7.71 months (95% CI 3.84-11.58m) in TP53-wild group (HR 0.68 [95% CI 0.38-1.23], p=0.175). The TP53-mutant group comprised 29 missense (17 DNA contact mutants and 12 conformational mutants), 6 frameshift, 6 truncating, 5 deletion, 4 splice, and 1 deletion-insertion mutation. In a subgroup analysis of patients with TP53 missense mutations, the mPFS was 21.36 months (95% CI 1.67-41.06m) in conformational mutant group and 10.64 months (95% CI 7.52-13.76m) in DNA contact mutant group (HR 0.41 [95% CI 0.14-1.17], p=0.110). The two curves intersect at the onset and then diverge distinctly. The study also found a significant improvement in PFS for patients with TP53 conformational mutant compared to those without TP53 mutations (mPFS: 21.36m vs. 7.71m, HR 0.36 [95% CI 0.16-0.82], p=0.047). Hence, the impact of TP53 mutation types on anti-PD-(L)1 antibody efficacy varies, and TP53 conformational mutants may be potential prognostic indicators for longer PFS in immunotherapy.
Conclusions
The impact of distinct TP53 mutation types on immunotherapy efficacy should be addressed separately. Patients with TP53 conformational mutations may exhibit prolonged PFS in response to anti-PD-(L)1 immunotherapy.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
22P - Extracellular vesicles as predictive biomarkers for chemoimmunotherapy in biliary tract cancer
Presenter: Michele Zanoni
Session: Poster Display session
Resources:
Abstract
23P - Non-small cell lung cancer DNA methylation profiles correlate with immune checkpoint inhibitor response
Presenter: Julia Berger
Session: Poster Display session
Resources:
Abstract
24P - Blood DNA methylation profiles in NSCLC patients treated with immune checkpoint inhibitors
Presenter: Markus Kleinberger
Session: Poster Display session
Resources:
Abstract
25P - Circulating tumor DNA is predictive of overall survival in patients with metastatic uveal melanoma
Presenter: Egle Ramelyte
Session: Poster Display session
Resources:
Abstract
26P - Liquid biopsy-based percision immunotherapy: CCAT1 and HEIH lncRNAs identify young breast cancer patients likely to respond to PD-L1 blockade
Presenter: Rana Youness
Session: Poster Display session
Resources:
Abstract
27P - Single cell RNA sequencing (scRNAseq) analysis of peripheral immune cell populations from patients treated with anti-PD1 with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Presenter: Séverine Carlier
Session: Poster Display session
Resources:
Abstract
28P - Circulating biomarkers in non-small cell lung cancer patients treated with immune checkpoint inhibitors
Presenter: Paola Ulivi
Session: Poster Display session
Resources:
Abstract
29P - Prognostic value of systemic inflammatory index and platelet-to-lymphocyte ratio in muscle-invasive bladder cancer patients treated with neoadjuvant chemo-immunotherapy in the AURA trial
Presenter: Jeremy Blanc
Session: Poster Display session
Resources:
Abstract
30P - The prognostic value of low density neutrophils in breast cancer: Implications for therapeutic strategies
Presenter: Telma Martins
Session: Poster Display session
Resources:
Abstract
31P - Peripheral-blood Immune-predictors of pathological complete response in patients with triple-negative breast cancer undergoing neoadjuvant chemo-immunotherapy
Presenter: Celeste Santoro
Session: Poster Display session
Resources:
Abstract